Time-varying SUVr reflects the dynamics of dopamine increases during methylphenidate challenges in humans

Commun Biol. 2023 Feb 10;6(1):166. doi: 10.1038/s42003-023-04545-3.

Abstract

Dopamine facilitates cognition and is implicated in reward processing. Methylphenidate, a dopamine transporter blocker widely used to treat attention-deficit/hyperactivity disorder, can have rewarding and addictive effects if injected. Since methylphenidate's brain uptake is much faster after intravenous than oral intake, we hypothesize that the speed of dopamine increases in the striatum in addition to its amplitude underly drug reward. To test this we use simulations and PET data of [11C]raclopride's binding displacement with oral and intravenous methylphenidate challenges in 20 healthy controls. Simulations suggest that the time-varying difference in standardized uptake value ratios for [11C]raclopride between placebo and methylphenidate conditions is a proxy for the time-varying dopamine increases induced by methylphenidate. Here we show that the dopamine increase induced by intravenous methylphenidate (0.25 mg/kg) in the striatum is significantly faster than that by oral methylphenidate (60 mg), and its time-to-peak is strongly associated with the intensity of the self-report of "high". We show for the first time that the "high" is associated with the fast dopamine increases induced by methylphenidate.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Attention Deficit Disorder with Hyperactivity*
  • Brain / metabolism
  • Dopamine / metabolism
  • Dopamine Antagonists / metabolism
  • Dopamine Antagonists / pharmacology
  • Dopamine Antagonists / therapeutic use
  • Humans
  • Methylphenidate* / pharmacology
  • Raclopride / metabolism
  • Raclopride / pharmacology
  • Raclopride / therapeutic use

Substances

  • Methylphenidate
  • Dopamine
  • Raclopride
  • Dopamine Antagonists